Figure 2.

Representative β-Tubulin immunofluorescence images in the microfluidic device after drug administration. To verify the response to the compounds, rat dorsal root ganglion (DRG) neurons were cultured on the MPS device, exposed to the compound on day 14, and immunostaining images were taken 24 h later. The compounds used included DMSO as a vehicle, sucrose as a negative compound, paclitaxel and vincristine as anticancer drugs that cause axonal damage, and oxaliplatin, which induces somatic cell damage. Additionally, bortezomib, a proteasome inhibitor reported to cause chemotherapy-induced peripheral neuropathy (CIPN), and suramin, an antiparasitic drug with antitumor effects known to cause myelin damage, were selected as test compounds: (A) Representative local immunofluorescence images of soma. From left: DMSO 0.1% and sucrose at 10 µM. Paclitaxel at 0.1 µM and paclitaxel at 1 µM. Vincristine at 0.003 µM and vincristine at 0.03 µM. Oxaliplatin at 10 µM and oxaliplatin at 100 µM. Suramin at 10 µM and suramin at 100 µM. Bortezomib at 0.01 µM. Scale bar = 20 μm. (B) Representative local immunofluorescence images of axons. From left: DMSO 0.1% and sucrose at 10 µM. Paclitaxel at 0.1 µM and paclitaxel at 1 µM. Vincristine at 0.003 µM and vincristine at 0.03 µM. Oxaliplatin at 10 µM and oxaliplatin at 100 µM. Suramin at 10 µM and suramin at 100 µM. Bortezomib at 0.01 µM. Scale bar = 200 μm.